Effect of Vitamin K Intake on the Stability of Treatment with Vitamin K Antagonists: A Systematic Review of the Literature

Abstract

Vitamin K antagonists (VKA) are highly effective for the primary and secondary prevention of arterial and venous thromboembolic events. However, patients treated with VKA have on average only 60% of their international normalized ratio (INR) values within the therapeutic range and INR instability is associated with an increased risk of thrombosis and bleeding events. Recent evidence suggests that poor dietary vitamin K intake may affect anticoagulation control, but the role of vitamin K in INR stability remains to be established. We performed a systematic review of the literature to assess the role of vitamin K dietary intake on the stability of VKA and the potential effect of daily vitamin K supplementation on VKA therapy. After a search in Medline and EMBASE databases, 15 studies for a total of 1,838 patients were included in our systematic review. Observational studies suggest an increased risk of unstable anticoagulation control in patients with lower daily vitamin K intake. On the other hand, the role of daily vitamin K supplementation or a diet with controlled vitamin K content in patients on VKA treatment remains to be established. Use of daily vitamin K supplementation may be associated with a clinically relevant increase in the time in therapeutic range in patients with unstable anticoagulation control. Conversely, this effect appears small and not clinically relevant when vitamin K was administered to an unselected population receiving VKA. Other large prospective studies are necessary to confirm our preliminary findings.

Keywords

vitamin K - INR stability - diet

• References

• 1 Kakkar AK, Mueller I, Bassand JP , et al; GARFIELD Registry Investigators. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. PLoS ONE 2013; 8 (5) e63479
• 2 Camm AJ, Lip GY, De Caterina R , et al; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33 (21) 2719-2747
• 3 You JJ, Singer DE, Howard PA , et al; American College of Chest Physicians. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl) e531S-e575S
• 4 Kearon C, Akl EA, Comerota AJ , et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl) e419S-e494S
• 5 van Walraven C, Jennings A, Oake N, Fergusson D, Forster AJ. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest 2006; 129 (5) 1155-1166
• 6 Hylek EM, Go AS, Chang Y , et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349 (11) 1019-1026
• 7 Pirmohamed M, James S, Meakin S , et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329 (7456) 15-19
• 8 Palareti G, Legnani C, Cosmi B, Guazzaloca G, Cini M, Mattarozzi S. Poor anticoagulation quality in the first 3 months after unprovoked venous thromboembolism is a risk factor for long-term recurrence. J Thromb Haemost 2005; 3 (5) 955-961
• 9 Hylek EM, Heiman H, Skates SJ, Sheehan MA, Singer DE. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA 1998; 279 (9) 657-662
• 10 Rohde LE, de Assis MC, Rabelo ER. Dietary vitamin K intake and anticoagulation in elderly patients. Curr Opin Clin Nutr Metab Care 2007; 10 (1) 1-5
• 11 Harris JE. Interaction of dietary factors with oral anticoagulants: review and applications. J Am Diet Assoc 1995; 95 (5) 580-584
• 12 McGinn T, Wyer PC, Newman TB, Keitz S, Leipzig R, For GG ; Evidence-Based Medicine Teaching Tips Working Group. Tips for learners of evidence-based medicine: 3. Measures of observer variability (kappa statistic). CMAJ 2004; 171 (11) 1369-1373
• 13 Jadad AR, Moore RA, Carroll D , et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996; 17 (1) 1-12
• 14 Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273 (5) 408-412
• 15 Deeks JJ, Dinnes J, D'Amico R , et al; International Stroke Trial Collaborative Group; European Carotid Surgery Trial Collaborative Group. Evaluating non-randomised intervention studies. Health Technol Assess 2003; 7 (27) iii-x , 1–173
• 16 Sorano GG, Biondi G, Conti M, Mameli G, Licheri D, Marongiu F. Controlled vitamin K content diet for improving the management of poorly controlled anticoagulated patients: a clinical practice proposal. Haemostasis 1993; 23 (2) 77-82
• 17 Sconce E, Khan T, Mason J, Noble F, Wynne H, Kamali F. Patients with unstable control have a poorer dietary intake of vitamin K compared to patients with stable control of anticoagulation. Thromb Haemost 2005; 93 (5) 872-875
• 18 Reese AM, Farnett LE, Lyons RM, Patel B, Morgan L, Bussey HI. Low-dose vitamin K to augment anticoagulation control. Pharmacotherapy 2005; 25 (12) 1746-1751
• 19 Couris R, Tataronis G, McCloskey W , et al. Dietary vitamin K variability affects International Normalized Ratio (INR) coagulation indices. Int J Vitam Nutr Res 2006; 76 (2) 65-74
• 20 Ford SK, Misita CP, Shilliday BB, Malone RM, Moore CG, Moll S. Prospective study of supplemental vitamin K therapy in patients on oral anticoagulants with unstable international normalized ratios. J Thromb Thrombolysis 2007; 24 (1) 23-27
• 21 Sconce E, Avery P, Wynne H, Kamali F. Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. Blood 2007; 109 (6) 2419-2423
• 22 Rombouts EK, Rosendaal FR, Van Der Meer FJ. Daily vitamin K supplementation improves anticoagulant stability. J Thromb Haemost 2007; 5 (10) 2043-2048
• 23 de Assis MC, Rabelo ER, Avila CW, Polanczyk CA, Rohde LE. Improved oral anticoagulation after a dietary vitamin k-guided strategy: a randomized controlled trial. Circulation 2009; 120 (12) 1115-1122 , 3, 1122
• 24 Rombouts EK, Rosendaal FR, van der Meer FJ. Influence of dietary vitamin K intake on subtherapeutic oral anticoagulant therapy. Br J Haematol 2010; 149 (4) 598-605
• 25 Kim KH, Choi WS, Lee JH, Lee H, Yang DH, Chae SC. Relationship between dietary vitamin K intake and the stability of anticoagulation effect in patients taking long-term warfarin. Thromb Haemost 2010; 104 (4) 755-759
• 26 Dalloul G, Ghanbari H, Hasan R , et al. The effect of vitamin K supplementation on anticoagulation stability in a community based cardiology practice. In: Proceedings of the 31st Annual Scientific Sessions of the Heart Rhythm Society, Heart Rhythm; May 12–15, 2010; Denver, CO
• 27 Gebuis EP, Rosendaal FR, van Meegen E, van der Meer FJ. Vitamin K1 supplementation to improve the stability of anticoagulation therapy with vitamin K antagonists: a dose-finding study. Haematologica 2011; 96 (4) 583-589
• 28 Zuchinali P, Souza GC, de Assis MC, Rabelo ER, Rohde LE. Dietary vitamin K intake and stability of anticoagulation with coumarins: evidence derived from a clinical trial. Nutr Hosp 2012; 27 (6) 1987-1992
• 29 Li RC, Finkelman BS, Chen J , et al. Dietary vitamin K intake and anticoagulation control during the initiation phase of warfarin therapy: a prospective cohort study. Thromb Haemost 2013; 110 (1) 195-196
• 30 Luck KK, Schreiber S, Duffey KE. Evaluation of the use of low-dose oral vitamin k in patients taking warfarin who have a low time in therapeutic range. J Thromb Thrombolysis 2013; 35 (3) 416
• 31 Majeed H, Rodger M, Forgie M , et al. Effect of 200μG/day of vitamin K1 on the variability of anticoagulation control in patients on warfarin: a randomized controlled trial. Thromb Res 2013; 132 (3) 329-335
• 32 Leblanc C, Presse N, Lalonde G, Dumas S, Ferland G. Higher vitamin K intake is associated with better INR control and a decreased need for INR tests in long-term warfarin therapy. Thromb Res 2014; 134 (1) 210-212
• 33 Wallin R, Sane DC, Hutson SM. Vitamin K 2,3-epoxide reductase and the vitamin K-dependent gamma-carboxylation system. Thromb Res 2002; 108 (4) 221-226
• 34 Garcia AA, Reitsma PH. VKORC1 and the vitamin K cycle. Vitam Horm 2008; 78: 23-33
• 35 Booth SL, Al Rajabi A. Determinants of vitamin K status in humans. Vitam Horm 2008; 78: 1-22
• 36 Kurnik D, Lubetsky A, Loebstein R, Almog S, Halkin H. Multivitamin supplements may affect warfarin anticoagulation in susceptible patients. Ann Pharmacother 2003; 37 (11) 1603-1606
• 37 Cushman M, Booth SL, Possidente CJ, Davidson KW, Sadowski JA, Bovill EG. The association of vitamin K status with warfarin sensitivity at the onset of treatment. Br J Haematol 2001; 112 (3) 572-577
• 38 Presse N, Kergoat MJ, Ferland G. High usual dietary vitamin K intake is associated with low relative variability in vitamin K intake: implications for anticoagulant therapy. Br J Haematol 2011; 153 (1) 129-130
• 39 Dentali F, Riva N, Crowther M, Turpie AG, Lip GY, Ageno W. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation 2012; 126 (20) 2381-2391
• 40 van Es N, Coppens M, Schulman S, Middeldorp S, Büller HR. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014; 124 (12) 1968-1975
• 41 Wallentin L, Yusuf S, Ezekowitz MD , et al; RE-LY investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376 (9745) 975-983
• 42 Wallentin L, Lopes RD, Hanna M , et al; Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Investigators. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation 2013; 127 (22) 2166-2176
• 43 Booth SL. Vitamin K status in the elderly. Curr Opin Clin Nutr Metab Care 2007; 10 (1) 20-23
• 44 Gadisseur AP, van der Meer FJ, Adriaansen HJ, Fihn SD, Rosendaal FR. Therapeutic quality control of oral anticoagulant therapy comparing the short-acting acenocoumarol and the long-acting phenprocoumon. Br J Haematol 2002; 117 (4) 940-946
• 45 Fihn SD, Gadisseur AA, Pasterkamp E , et al. Comparison of control and stability of oral anticoagulant therapy using acenocoumarol versus phenprocoumon. Thromb Haemost 2003; 90 (2) 260-266
• 46 Van Leeuwen Y, Gebuis EPA, van der Meer FJM , et al. Late breaking clinical trial: a randomized comparison of the quality of anticoagulant therapy with two vitamin K antagonists: warfarin versus phenprocoumon. J Thromb Haemost 2009; 7: 1202-1204